CPPs (cell-penetrating peptides), including Tatp (transactivator of transcription peptide), have been successfully used for intracellular delivery of a wide variety of cargoes including various nanoparticulate pharmaceutical carriers such as liposomes, micelles and nanoparticles. Here, we will consider the major results obtained in this area with emphasis on Tatp-mediated delivery of liposomes and various transfection vectors. We will also address the development of 'smart' stimuli-sensitive nanocarriers, where the cellpenetrating function can only be activated when the nanocarrier is inside the biological target, thus minimizing the interaction with non-target cells.
Tatp-mediated intracellular delivery of pharmaceutical nanocarriers Intracellular delivery of nanoparticles by CPPs (cell-penetrating peptides)
Over the last decade, CPPs, including Tatp (transactivator of transcription peptide) and various oligoarginines, have been widely exploited for the intracellular delivery of differently sized cargo in a range of cell types, both in vitro and in vivo. The cargo delivered ranged from peptides, proteins, genetic material, antibodies, imaging agents and toxins to nanoparticles and liposomes. A complete review of the different major cargoes delivered by CPPs can be found in [1] .
The first example of CPP-mediated nanoparticulate delivery was described in 1999 [2] . This first study demonstrated that iron oxide nanoparticles, when coupled to Tatp, efficiently label cells and so may serve as a tool for MRI (magnetic resonance imaging) or magnetic separation of homed cells in vivo. For this purpose, CPPs, such as Tatp-48-57, were coupled to the dextran-coated superparamagnetic CLIOs (cross-linked iron oxide particles). The average size of the particles was 41 nm and the conjugate carried, on average, 6.7 Tatp moieties per particle. In all cell lines tested (mouse lymphocytes, human natural killer cells and HeLa cells), the uptake of Tatp-CLIO nanoparticles was approx. 100-fold higher than that of the non-modified CLIO. The fluorescence microscopy studies on live cells revealed that the conjugate first accumulated in lysosomes and this was followed by intense localization in the nucleus. The experiments clearly suggested that Tatp-modified CLIOs are superior to Tatpfree particles as tools for intracellular labelling. Tatp-CLIO nanoparticles were also examined to determine whether they could be employed to track progenitor cells under in vivo conditions [3] . The magnetic labelling of both stem cells and progenitor cells allowed observation of their migration and facilitated cell imaging by MRI under physiological conditions and so may be relevant for the application of stem cells in therapeutics. Another study conducted using the Tatp-CLIO-labelled cells and MRI found that T-cells were magnetically labelled without affecting their normal response to stimulation. Upon intravenous injection, the homing of T-cells to the spleen could be detected by MRI and their biodistribution profile followed by MRI in vivo [4] . Another study observed the uptake of Tatp-labelled iron oxide particles by T-cells, B-cells and macrophages over 72 h and found that uptake of the particles was rapid, with no decrease in cell viability [5] . However, the Tatp-iron oxide conjugates were accumulated primarily in the cytoplasm, in contrast with the nuclear localization observed in other studies.
The effect of Tatp density per CLIO particle on the sensitivity of MRI detection was also investigated. The cellular uptake of Tatp-CLIO by mouse lymphocytes was investigated using different Tatp/CLIO ratios. The cellular uptake of the Tatp-CLIO particles increased in a non-linear fashion upon increasing of the Tatp/CLIO ratios; this gave a 100-fold increase in cell uptake with 15 Tatp per CLIO particle compared with control. The labelling of cells with higher Tatp/CLIO ratio conjugates significantly enhanced the sensitivity of MRI; thus cells could be tracked at approx. 100-fold lower concentrations by use of higher Tatp/CLIO ratio conjugates [6] . In vivo studies on mice showed that the attachment of Tatp to iron oxide nanoparticles reduced the half-life of the conjugate in the blood [7] . Both the Tatp-modified and non-modified iron oxide nanoparticles were removed from the circulation by the RES (reticuloendothelial system). However, their distribution profiles within the RES differed: the non-modified nanoparticles accumulated along the hepatic vessels in the endothelial and/or Kupffer cells, whereas Tatp-modified iron oxide nanoparticles were distributed intensely throughout the parenchyma. Subcellular analysis revealed the nuclear accumulation of Tatp-iron oxide nanoparticles.
Modification of the surface of nanoparticles with CPPs resulted in the enhancement of cell permeability of nanoparticulate-based therapeutics [8] . When the surface of the CLIOs was modified with either D-polyarginine peptides or Tatp, the nanoparticles could traverse through the cell monolayers. Such nanoparticles could be used for labelling of immune cells for in vivo imaging purposes [9] . The same approach was applied to prepare octa-arginine-coated liposomes to target airway cells by inhalation [10] .
Tatp-modified nanoparticles have also been investigated for their capability to deliver diagnostic and therapeutic agents across the blood/brain barrier [11] . FSNPs (fluorescein-doped silica nanoparticles) were modified by addition of Tatp. Tatp-conjugated FSNPs which were administered intra-arterially to the brains of rats were shown to label the brain blood vessels, demonstrating the potential for delivery of therapeutic agents to the brain.
CPP-modified quantum dot-loaded polymeric micelles were used for labelling cells with quantum dots [12] . Quantum dots were trapped within micelles prepared from PEG [poly(ethylene glycol)]-PE (phosphatidylethanolamine) conjugates containing the Tatp-PEG-PE component. Tatp-quantum dot conjugates could label mouse endothelial cells in vitro. For in vivo tracking, bone marrow-derived progenitor cells were labelled with Tatp-quantum dot conjugate-containing micelles ex vivo, and then the cells were injected into mice presenting a tumour in a cranial window model. It was possible to track the movement of labelled progenitor cells to the tumour endothelium and this will be beneficial in the understanding of the fine details of tumour neovascularization.
Intracellular distribution studies conducted on Tatp PTD (protein transduction domain)-modified gold nanoparticles suggested that the conjugates were internalized by endocytosis and did not localize into the nuclei of NIH-3T3 or HepG2 cells [40] . In contrast, de la Fuente and Berry [13] showed that Tatp-modified gold nanoparticles traversed through the plasma membrane of human fibroblast cells and accumulated within the nuclei. Tatp-conjugated boron carbide nanoparticles were also translocated into murine EL4 lymphoma cells and B16F10 melanoma cells, which suggests an approach towards more effective boron neutron-capture therapy [14] .
CPPs have also been used for enhanced delivery of liposomal drug carriers. Tatp-modified liposomes have been delivered intracellularly in different cell lines, such as murine LLC (Lewis lung carcinoma) cells, human breast tumour BT20 cells and rat cardiac myocyte H9C2 cells [15, 16] . The liposomes were tagged with Tatp via the spacer pNP (p-nitrophenylcarbonyl)-PEG-PE at a density of approx. 500 Tatp moieties per 200 nm liposome. Cells treated with liposomes in which Tatp-cell interaction was hindered, either by the direct attachment of Tatp to the liposome surface or by long PEG grafts on the liposome surface shielding the Tatp moiety, did not show Tatp-liposome internalization. However, Tatp-liposomes, which allowed direct contact of Tatp residues with cells, displayed an enhanced uptake into cells. This suggested that the penetration of Tatp-liposomes into cells requires the direct interaction of Tatp with the cell surface.
Another study examined the kinetics of uptake of Tatp-and penetratin-modified liposomes. It was found that intracellular delivery of liposomes by Tatp or penetratin was proportional to the number of peptide molecules attached to the liposome surface. As few as five peptides was sufficient to enhance the intracellular delivery of liposomes. The kinetics of the uptake was peptide-and cell-type-dependent. For Tatp-liposomes, the intracellular accumulation was time-dependent. Accumulation in the penetratin-liposomes was rapid, reaching a peak within 1 h, after which it gradually declined [17] .
Similarly, Antp (Antennapedia peptide)-(43-58) and Tatp coupled to small unilamellar liposomes accumulated in higher proportions within tumour cells and dendritic cells than in unmodified control liposomes [18] . The uptake was time-and concentration-dependent, and at least 100 PTD molecules per small unilamellar liposome were required for efficient uptake into cells. The uptake of modified liposomes was inhibited by the pre-incubation of liposomes with heparin, confirming the role of heparan sulfate proteoglycans in CPPmediated uptake. The coupling of Tatp to the outer surface of liposomes was also found to result in an enhanced binding and endocytosis of the liposomes in ovarian carcinoma cells [19] .
Some data relating to the intracellular delivery of pharmaceutical nanocarriers are presented in Table 1 .
Tatp-modified nanocarriers for delivery of nucleic acids
CPPs have also been used to enhance gene delivery by various nanocarriers. Thus SLNs (solid lipid nanoparticles) have been used for this purpose [20] . A SLN gene vector was modified with dimeric Tatp (Tatp2), and the presence of Tatp2 in SLN enhanced the transfection efficiency both in vitro and in vivo. In another study, Tatp conjugated to nanocage structures also provided enhanced binding and penetration into cells in vitro [21] . The SCK (shell cross-linked) nanoparticles prepared by the formation of micelles of amphiphilic block copolymers of poly(ε-caprolactone-b-acrylic acid) conjugated to Tatp have been incubated with CHO (Chinese hamster ovary) and HeLa cells and demonstrated increased binding and penetration into cells. The authors then characterized the SCK nanoparticles to determine the optimum number of Tatp per particle required to enhance the transfection efficiency [22, 23] . Tatp-functionalized polymeric nanoparticles (complexes of polyethyleneimine and DNA) effectively delivered gene vectors into undifferentiated and differentiated SH-SY5Y cells [24] . In a different approach, to improve the transfection and protect the DNA from degradation, TCLs (thiocholesterol-based cationic lipids) were used in the formation of NLPs (nanolipoparticles). The NLPs were For boron neutron capture therapy [14] sequentially modified with Tatp; this resulted in Tatp-NLPs with a zwitterionic surface and higher transfection efficiency than for the cationic NLPs alone [25] . The conjugation of Tatp to lipoplexes enhanced the gene transfection in primary cell cultures by endocytic uptake [26] . It was also shown that Tatp-modified lipoplexes are mainly internalized by cells via a cholesterol-dependent clathrin-mediated pathway [27] . Tatp-liposomes have also been used for gene delivery. We have shown that Tatp-liposome-DNA complexes, when incubated with mouse fibroblast NIH-3T3 cells and cardiac myocyte H9C2 cells, demonstrated a substantially higher transfection in vitro, with lower cytotoxicity than the commonly used Lipofectin R . Under in vivo conditions, intratumoral injection of Tatp-liposome-DNA complexes, containing a plasmid encoding GFP (green fluorescent protein), into a LLC tumour in mice resulted in efficient transfection of the tumour cells (intensive green staining of tissue sections in the case of Tatp-modified DNA-liposomes, not observed upon injection of Tatp-free DNA-liposomes) [16] . We also recently investigated the potential of Tatp-modified liposomes to enhance the delivery of pEGFP-N1, a plasmid encoding GFP and used as a model gene in this case, to human brain tumour U-87 MG cells in vitro and in an intracranial model in nude mice [28] . The size distribution of DNAloaded Tatp injections of Tatp-lipoplexes showed an enhanced delivery of pEGFP-N1 selectively to tumour cells and efficient transfection compared with plain plasmid-loaded lipoplexes.
No transfection was noted in the normal brain adjacent to the tumour (Figure 1 ). Thus Tatp-lipoplexes can be used to augment the delivery of genes to tumour cells when injected intratumorally, without affecting the normal adjacent brain.
Tatp as a component of 'smart' nanoparticulate stimuli-sensitive delivery systems
A nanoparticular DDS (drug-delivery system) should specifically accumulate in the required organ or tissue and then penetrate inside target cells, delivering its cargo (drug or DNA). Organ or tissue (tumour, infarct) accumulation could be achieved by passive targeting via the EPR (enhanced permeability and retention) effect [29, 30] which is assisted by prolonged circulation of such nanocarriers (for example, as a result of the carrier being coated with a protecting polymer, e.g. PEG) or by antibody-mediated active targeting [31, 32] . The intracellular delivery of the nanocarrier could be mediated by certain internalizable ligands (folate, transferrin) [33, 34] or by CPPs [1, 35] . Such DDSs should present various active moieties on the shuttle surface, in order to be multifunctional and only reveal certain functions only when necessary, e.g. under stimuli characteristic of the target pathological zone (increased temperature or lowered pH are characteristic of inflamed, ischaemic and neoplastic tissues). Such DDSs should be engineered in a manner so that, during the first phase of delivery, a non-specific cell-penetrating function is shielded by organ/tissue-specific delivery (mediated by a sterically protecting polymer or antibody). Upon accumulation in the target area, the protecting polymer or antibody attached to the surface of the DDS via the stimuli-sensitive bond should become detached under the action of local pathological conditions (such as abnormal pH or temperature) and expose the previously hidden second function, allowing for the subsequent delivery of the carrier and its cargo inside cells.
With this in mind, we have designed and tested targeted long-circulating PEGylated liposomes and PEG-PE-based micelles with several functions [36, 37] . These liposomes and micelles were capable of targeting a specific cell or organ by attaching the monoclonal anti-myosin antibody 2G4 to their surface via pNP-PEG-PE moieties. The liposomes and micelles were additionally modified by attachment of Tatp moieties to the surface of the nanocarrier by use of Tatp-short PEG-PE derivatives. The PEG-PE used for liposome surface modification or for micelle preparation was made degradable by inserting the pH-sensitive Hz (hydrazone) bond between PEG and PE (PEG-Hz-PE). Under normal pH values, Tatp functions on the surface of nanocarriers were 'shielded' by long protecting PEG chains (pH-degradable PEG 2000 -PE or PEG 5000 -PE) or by longer pNP-PEG-PE moieties used to attach antibodies to the nanocarrier (non-pH-degradable PEG 3400 -PE or PEG 5000 -PE). At pH 7.5-8.0, both liposomes and micelles demonstrated high specific binding with the antibody substrate myosin, but very limited internalization by either NIH-3T3 or U-87 cells. However, after a brief incubation (15-30 min) at a lower pH (pH 5.0-6.0), nanocarriers shed their protective PEG shell owing to hydrolysis of PEG-Hz-PE and so were able to be effectively internalized into cells via the Tatp moieties ( Figure 2) .
In vivo, Tatp-modified GFP-loaded liposomal preparations were administered directly into tumours in tumourbearing mice, and the efficacy of tumour cell transfection was followed 72 h after transfection. The administration of pGFP-Tatp-liposomes with a non-pH-sensitive PEG coating resulted in only minimal transfection of tumour cells because of steric hindrances for liposome-cell interaction caused by the PEG coat, which shielded the surface-attached Tatp. At the same time, administration of GFP-Tatp-liposomes with the low pH-sensitive PEG resulted in the highly efficient transfection since the removal of PEG by the low intratumoral pH leads to exposure of the liposome-attached Tatp residues, enhanced penetration of liposomes inside tumour cells and more effective intracellular delivery of the the model gene, pEGFP-N1 [38] .
Tatp-modified stimuli-sensitive polymeric micelles with an enhanced ability to interact with cells under acidified conditions have also been described recently [39] . These findings are an important step in the development of tumourspecific stimuli-sensitive drug-and gene-delivery systems.
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